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1 Introductory Summary 
 Relevance 
Health-related quality of life (HRQoL) is a multidimensional construct to measure and evaluate 
the health perception of individuals or groups [1]. Compared to hard outcomes such as survival, 
HRQoL is more versatile and accounts for the multi-layered nature of health states. Both the 
European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) 
recognize the importance of HRQoL for clinical trials [2-4]. Moreover, registries for elective 
surgery in England and Sweden gather HRQoL on a routine basis [5, 6], while a wide variety of 
studies include or focus on HRQoL as an outcome of interest [7-13]. As shown in Figure 1, a key 
word count on PubMed illustrates the increasing importance of HRQoL in the scientific 
literature since 1994.  
 
Figure 1 Key word count for ‘health-related quality of life’ on PubMed 
Despite these developments, barriers to implement HRQoL for primary and secondary care 
exist, and effective improvement of quality of care from the patient perspective is still needed 
[14].  
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 Aims 
To improve the understanding of health perception and to foster the implementation of HRQoL 
in clinical practice, this thesis evaluates three aspects of HRQoL research. This is done using 
three articles, moving from the macro (country-level) to the micro (patient-level) perspective.  
By evaluating the results of a cross-sectional survey in Germany from 2015, the aim of the first 
article is to supply an accurate description of individuals’ perceptions of their own health 
(henceforth, health perception) in a representative sample of the general German population. 
The article complements previous population studies [15-17]. Component analysis is used to 
evaluate the influence of valuation and description on health perception changes over the 
evaluated years. Sociodemographic variables, comorbidities, and other variables are evaluated 
to identify possible drivers of HRQoL. 
The second article connects to the first one by focusing on those survey participants who 
reported being problem-free. Despite not indicating any problems in the descriptive parts of 
one HRQoL instrument, many older participants stated significantly lower values for their 
aggregated health perception [17]. The association between increasing age and reduced health 
perception is well documented [13–15], but the decline in aggregated health perception among 
people reporting being otherwise problem-free nevertheless deserves attention, because it 
reflects discrepancy between what people perceive and what values are reported for further 
evaluation. 
The third article supplements the first two by testing new methods to predict patient-reported 
outcomes (PROMs) that are based on HRQoL, following hip and knee replacement surgery. It 
incorporates linear and machine learning based prediction models. The aim is to find the best 
performing model, measured by respective metrics, and to identify the most important 
variables. Practical aspects and clinical relevance of PROMs prediction are discussed. The 
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overall goal of the third article is to improve shared decision-making between doctors and 
patients by enabling better estimation of outcomes following hip and knee replacement surgery. 
 Methods 
1.3.1 Data 
Article 1 and 2 evaluate data from an annual survey in Germany that gathers information about 
health trends and health status. To include a representative sample of the German population, 
the survey uses a random-route procedure to select participating households. The survey is of 
high quality and allows to spot annual changes of overall health status. Article 3 uses routinely 
gathered registry data for hip and knee replacement surgery from the National Health Service 
(NHS). Due to its significant number of yearly observations and the included variables, this 
provider-based dataset is an excellent source to train prediction models. No comparable dataset 
could be accessed for Germany. Both datasets incorporate validated and widely accepted 
instruments to measure HRQoL.  
1.3.2 Instruments to measure health-related quality of life 
Instruments to measure HRQoL can be divided into two main categories: generic and disease-
specific [18]. As implied by their names, disease-specific instruments are developed for specific 
health conditions, to address specific symptoms associated with disease. For example, the 
Oxford Hip Score (OHS) [19], which is used in Article 3, consists of 12 questions highly related 
to problems with the hip (e.g. hip pain or the ability to walk). On the other hand, generic 
instruments are applicable across different populations as well as interventions. They 
incorporate more general questions, for instance concerning overall pain or the ability to 
complete daily tasks. A widely accepted and validated generic instrument is the EQ-5D-3L/5L 
[20], which is used in all three articles in this thesis. The EQ-5D-5L is a newer version of the EQ-
5D-3L questionnaire; the former includes only three answer levels for each dimension, while the 
latter includes five. Both versions consist of five questions, called dimensions, and the visual 
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analog scale (VAS). The five dimensions of the EQ-5D-3L/5L are mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression. Based on their answers, patients report a 
health state that is transformed into a five-digit number. For example, 11111 indicates no 
problems in all five dimensions, while 55555 is the worst possible health state, translating into 
extreme problems. Survey takers are also asked to mark their current health state on the VAS, 
which is an overall measure of patient health perception on the day of the survey. It ranges from 
0 (worst state) to 100 (best state). The psychometric properties of the EQ-5D-3L/5L have been 
evaluated across different diseases [21-24], and the questionnaire is used by a wide variety of 
arthroplasty registries worldwide [25].  
1.3.3 Valuing health states 
To support allocation decisions in health care and to evaluate HRQoL, health states often need 
to be valued via value sets. Value sets provide one corresponding index value for every possible 
health state (e.g. 1 for the problem-free health state of 11111 in the EQ-5D-5L). Otherwise, it would 
be difficult to differentiate between the same answer levels across different dimensions. For 
example, are slight problems with walking as inconvenient as slight pain? Value sets can mainly 
be divided into two categories. To create population-based value sets, people from the general 
public value hypothetical health states, while to form experience-based value sets, study 
participants who actually experience respective health states express their perception. Different 
approaches, such as time-trade-off (TTO) or standard gamble (SG), are used in valuation 
studies. With TTO, participants waive time for perfect health; with SG, they make probability-
based decisions for health status. Anchoring scales [26] and response shift [27] are also 
important methodological aspects but go beyond the scope of this thesis. Furthermore, since 
health perception differs across countries, country-specific value sets exist, such as for England 
[28], Sweden [29], and Germany [26, 30, 31].  
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There is some discussion concerning whether population perception or patient experience 
should be used for value sets [32-35]. For example, population-based value sets may not be fully 
informed, since participants do not experience respective health states [36]. Moreover, 
convincing arguments exist, to use VAS valuation for cost-utility analysis [37]. Article 2 accounts 
for this issue by comparing the VAS results of the most prevalent health state – namely being 
problem-free – with the most commonly assigned values for this health state. Articles 1 and 3 
do not incorporate value sets. In addition to the EQ-5D-3L, Article 3 also uses the OHS and 
Oxford Knee Score (OKS). All three instruments are well accepted, and they are incorporated 
by respective registries for elective surgery as PROMs [38].  
1.3.4 Patient-reported outcome measures 
According to the FDA, one inherent feature of PROMs is that they directly measure patients’ 
health perception, without interference from anyone else [39]. PROMs capture the health 
perception of patients at one or more points in time, such as before and following surgery. 
PROMs improve quality of care by enabling comparison of service providers, but they also make 
it possible, among others, to determine efficacy, cost effectiveness, and triggers for surgery [38]. 
Furthermore, the information provided by PROMs can be used to support shared decision-
making between doctors and patients to estimate likely intervention outcomes. By preventing 
unnecessary or harmful procedures, PROMs can improve health and reduce societal costs [40]. 
The NHS PROMs Programme and the Swedish quality registers successfully implement routine 
PROMs collection for elective surgery on a national scale [6]. Both registries use generic as well 
as disease-specific instruments, and they gather PROMs shortly before and at least 6 or 12 
months following surgery. In contrast, despite being among the top four OECD countries where 
hip and knee replacement surgeries are performed [41], German quality registers do not gather 
PROMs on a routine basis, nor do they make their data publicly available. Therefore, public 
NHS PROMs data is used in Article 3. The quality of this data is good but restrictive in some 
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ways (e.g. age groups instead of actual patient age are reported), to conform to data privacy 
protection standards. 
1.3.5 Minimal important differences 
Since changes in HRQoL between pre and post intervention can be very small, it is important 
to know what is relevant for patients. Minimal important differences (MIDs) have been 
developed to this end. MIDs define changes in HRQoL that are relevant or meaningful to 
patients [42, 43]. For example, the MID for patients with chronic obstructive pulmonary disease 
undergoing pulmonary rehabilitation has been estimated to be around 8 points for the EQ-5D-
5L VAS [44]. For the EQ-5D-5L index score, MIDS were estimated to range from 0.037 to 00.69, 
depending on country [45]. MIDs differ by patient population, disease, and instrument. A 
change that is relevant or meaningful for one patient may not be relevant or meaningful for 
another. Thus, MIDs must be case specific. Two of the most commonly used methods to 
calculate MIDs are anchor-based (external indicators to measure change)  and distribution-
based (statistical distribution of HRQoL in a sample) approaches [46]. The former uses external 
indicators and the latter uses statistical distributions of observed HRQoL scores to measure 
relevant change [46]. When suitable, MIDs can also be incorporated from the available 
literature. In all three articles in this thesis, results are evaluated in reference to respective MIDs. 
Article 3 also uses MIDs to define the binary states of ‘improvement’ and ‘no improvement’ 
following surgery.  
1.3.6 Statistical evaluation 
The three articles in this thesis use different evaluation methods, including descriptive analysis, 
linear approaches, and machine learning. Descriptive methods – used in all three articles of this 
thesis – describe characteristics or summarize overall findings such as age distributions, while 
linear regression evaluates the relationship between one or more variables and a response 
variable. Linear models are very fast and can be interpreted easily, but machine learning 
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sometimes offers better predictive performance, mostly at the cost of explanatory insight [47]. 
Interestingly, despite being highly popular lately, many machine learning algorithms can be 
dated back several decades [48, 49]. Machine learning is part of artificial intelligence (AI), which 
covers algorithms that enable computers to learn from experience [50]. Article 3 benchmarks 
linear against machine learning models. Because there is no free lunch in optimization, no 
model works best for all problems and comparison becomes necessary to reach maximal 
preditive performance [51]. To better understand what is referred to by machine learning in this 
context, it should be noted that machine learning can be divided into three main paradigms: 
supervised machine learning, unsupervised machine learning, and reinforcement learning [52]. 
Of these three categories, supervised machine learning is the most prevalent. It works by 
mapping predictors to pre-defined outcomes, for example, when preoperative variables are used 
to predict postoperative outcomes. Unsupervised machine learning, on the other hand, is 
mainly used for pattern detection, when data is not labeled and no pre-defined outcomes exist. 
The third paradigm, reinforcement learning, tries to maximize rewards by optimizing sequential 
behavior. Recent popular examples of AI incorporating reinforcement learning are AlphaGo 
[53], its successor AlphaGo Zero [54], and the follower Alpha Zero [55]. These AIs have not only 
beat the world’s best human players in specific games, but they have also become increasingly 
efficient at beating other world-leading AIs in decreasing amounts of time [54]. However, given 
the research aims and data, only supervised machine learning is considered in this thesis.  
 Results summary   
Article 1 reports stability in the health perception of the general German population over the 
last years. Age, depression, heart disease, and diabetes contribute significantly to reductions in 
perceived health. A slight increase in health perception compared with 2012 can be traced back 
to a higher number of participants in the problem-free health state. Compared with other 
countries, like Spain, England, and Canada, health perception in Germany (mean VAS of 85.1) 
was and is on a high level. 
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Next, Article 2 identifies systematic variation in health perception among the EQ-5D-5L study 
population, and especially among older participants with comorbidities. Diabetes and obesity 
are significantly associated with reporting lower VAS scores in the problem-free health state. 
The basic principle of current value sets – assigning one value for one health state – partly fails 
to reflect this patient/participant heterogeneity, since perceived health status may go beyond 
what is captured in the descriptive system of the EQ-5D-5L. 
Finally, Article 3 delivers benchmark results for several machine learning and linear patient 
outcome prediction models following hip and knee replacement surgery. Overall, some 
machine learning classifiers, such as extreme gradient boosting, mostly outperform linear 
alternatives, but the margin is small. Predicting generic improvement (VAS) is easier than 
predicting disease-specific improvement (OHS/OKS). Preoperative generic and disease-specific 
HRQoL are the most important predictors for the corresponding postoperative outcome. 
Benchmarking of different models is needed to maximize predictive performance and to find 
the optimal prediction model.  
Detailed results are provided in the corresponding section of each article. 
 Conclusion and outlook 
Moving from the macro to the micro (patient-level) perspective, this dissertation illustrates the 
importance of measuring and evaluating HRQoL for patient management. Routine gathering of 
HRQoL for representative samples of the general German population is necessary to identify 
trends and to measure the effects of health policy decisions. Reductions in perceived health 
should be counteracted. Moreover, with an increasing patient focus, health perception and 
individual valuation decisions should be discussed more openly. Finally, to foster shared 
decision-making between doctors and patients, accurate prediction models are needed, and 
machine learning offers new and interesting ways to build them. Recent technological and 
methodological advances as well as significant cost increases make it important to evaluate what 
patients want – namely, to improve their individual health state.  
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